Detalhe da pesquisa
1.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler;
26(1): 48-56, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30785358
2.
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler;
26(14): 1866-1876, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31762387
3.
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Mult Scler;
25(9): 1273-1288, 2019 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30986126
4.
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Neurology;
89(11): 1107-1116, 2017 Sep 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28835401
5.
Clinical outcomes of the REALIZE adjustable gastric band-C at one year in a U.S. population.
Surg Obes Relat Dis;
8(3): 288-95, 2012.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21775219
6.
Electromagnetic absorption in the head of adults and children due to mobile phone operation close to the head.
Electromagn Biol Med;
25(4): 349-60, 2006.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17178592